Impact of foslevodopa/foscarbidopa infusion on autonomic symptoms in advanced Parkinson’s Disease
Objective: To investigate the impact of continuous subcutaneous foslevodopa/foscarbidopa infusion (CSFLI) on autonomic symptoms in patients with advanced Parkinson’s disease (aPD) Background: CSFLI is a…Immunological principles of levodopa therapy in Parkinson’s disease
Objective: Study of the relationship between serum IL-10 levels in patients with Parkinson's disease and levodopa therapy Background: In Parkinson's disease, dehydroepiandrosterone can lead to…Continuous Subcutaneous Levodopa Therapy Improves Motor Fluctuations and Quality of Life in Parkinson’s Disease: Evidence from Meta-analysis of Clinical Trials
Objective: To evaluate the efficacy and safety of subcutaneous levodopa/carbidopa or prodrug infusions in reducing OFF-time and improving quality of life in patients with Parkinson’s…Three Different Behavioral Trajectories in L-DOPA–Treated Parkinson’s Disease Patients
Objective: To test the hypothesis that chronic pain may be associated with higher levodopa equivalent daily dosage (LEDD), and that patients who develop artistic creativity…Medical Management of Late-stage Parkinson’s Disease – a Cross-sectional, Multinational Survey
Objective: To investigate disease characteristics and common drug treatment of late-stage Parkinsons’ disease (LSPD). Background: LSPD presents with disabling motor and non-motor symptoms, the latter…Does Knowing More Mean Tolerating More? Satisfaction with Medication Information and Levodopa Dosage in Parkinson’s Disease
Objective: To characterize the correlation between satisfaction with medication-related information and daily levodopa dosage in Parkinson’s disease (PD) patients presenting with levodopa-related complaints. Background: Adequate…Foslevodopa-Foscarbidopa Continuous Subcutaneous Infusion Leads to Long-Term Reduction in Dyskinesia in Parkinson’s Disease: Results from 5-Year Follow-Up
Objective: To investigate the long-term impact of foslevodopa-foscarbidopa continuous subcutaneous infusion (CSCI) on dyskinesia in Parkinson’s disease (PD). Background: Foslevodopa-foscarbidopa CSCI is an emerging treatment…Parkinsonism Induced By An Interpeduncular Cistern Epidermoid Cyst A Case Report And Literature Review
Objective: To describe a patient with parkinsonism secondary to an interpeduncular cistern cyst causing midbrain compression, highlighting clinical features, structural and molecular imaging findings, and…Unravelling the neural correlates of visual cueing in Parkinson’s disease
Objective: Visual cueing can compensate for impaired automatic gait control in Parkinson's disease (PD) patients experiencing Freezing of Gait (FOG) by engaging goal-directed motor behaviour1.…Disrupted Sleep and Daytime Sleepiness are Associated With Poorer Quality of Life in Advanced Parkinson’s Disease: ROSSINI Interim Results
Objective: To evaluate correlations between real-world (RW) improvements in Parkinson’s disease (PD)-related sleep disturbances with foslevodopa/foscarbidopa (LDp/CDp) treatment, daytime sleepiness, and quality of life (QoL).…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 70
- Next Page »